Literature DB >> 19601803

Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.

Shu-Feng Zhou1, Jun-Ping Liu, Xin-Sheng Lai.   

Abstract

CYP2D6 accounts for only a small percentage of total hepatic CYPs (<2%), but it metabolizes approximately 25% of clinically used drugs (>100) with significant polymorphisms. A number of drugs acting on the central nervous system and cardiovascular system are substantially metabolized by CYP2D6. The enzyme also utilizes hydroxytryptamines and neurosteroids as endogenous substrates. In addition, CYP2D6 metabolizes procarcinogens and neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1,2,3,4-tetrahydroquinoline, and indolealkylamines. Typical CYP2D6 substrates are usually lipophilic bases with a planar hydrophobic aromatic ring and a nitrogen atom which can be protonated at physiological pH, but several atypical substrates such as spirosulfonamide and pactimibe do not contain a basic nitrogen atom. The structure of human CYP2D6 has been recently determined and shows the characteristic CYP fold as observed in other members of the CYP superfamily, with a well-defined active site cavity above the heme group with a volume of approximately 540 A(3). CYP2D6 is largely uninducible by prototypical CYP inducers such as phenobarbital, rifampin and dexamethasone, but it is regulated by hepatocyte nuclear factor-4alpha, a nuclear receptor. CYP2D6 is subject to inhibition by a number of drugs and this may provide an explanation for numerous clinical drug interactions. CYP2D6 has an important role in drug development and it is a common practice for pharmaceutical industry nowadays to a great extent screen drug candidates early in development as possible CYP2D6 substrates and/or inhibitors and drop such candidates where they have alternatives. This candidate selection might eventually lead to a less prominent role of this enzyme in the future for drug metabolism and less interindividual variability in drug exposure and minimize potentially adverse drug interactions. Further studies are warranted to delineate the molecular mechanisms involved in the function and regulation of CYP2D6.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19601803     DOI: 10.2174/092986709788681985

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  14 in total

Review 1.  Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing.

Authors:  Yao Yang; Mariana R Botton; Erick R Scott; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2017-05-04       Impact factor: 2.533

2.  Understanding the determinants of selectivity in drug metabolism through modeling of dextromethorphan oxidation by cytochrome P450.

Authors:  Julianna Oláh; Adrian J Mulholland; Jeremy N Harvey
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-28       Impact factor: 11.205

3.  Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s.

Authors:  Bo Lindmark; Anna Lundahl; Kajsa P Kanebratt; Tommy B Andersson; Emre M Isin
Journal:  Br J Pharmacol       Date:  2018-04-19       Impact factor: 8.739

4.  Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice.

Authors:  Ying Guo; Chad Pope; Xingguo Cheng; Honghao Zhou; Curtis D Klaassen
Journal:  J Ethnopharmacol       Date:  2011-09-06       Impact factor: 4.360

5.  RS-Predictor models augmented with SMARTCyp reactivities: robust metabolic regioselectivity predictions for nine CYP isozymes.

Authors:  Jed Zaretzki; Patrik Rydberg; Charles Bergeron; Kristin P Bennett; Lars Olsen; Curt M Breneman
Journal:  J Chem Inf Model       Date:  2012-05-29       Impact factor: 4.956

6.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 7.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.

Authors:  Tao Long; Rodrigo Cristofoletti; Brian Cicali; Veronique Michaud; Pamela Dow; Jacques Turgeon; Stephan Schmidt
Journal:  J Clin Pharmacol       Date:  2021-09-20       Impact factor: 2.860

9.  Automated design of paralogue ratio test assays for the accurate and rapid typing of copy number variation.

Authors:  Colin D Veal; Hang Xu; Katherine Reekie; Robert Free; Robert J Hardwick; David McVey; Anthony J Brookes; Edward J Hollox; Christopher J Talbot
Journal:  Bioinformatics       Date:  2013-06-06       Impact factor: 6.937

10.  Construction of Metabolism Prediction Models for CYP450 3A4, 2D6, and 2C9 Based on Microsomal Metabolic Reaction System.

Authors:  Shuai-Bing He; Man-Man Li; Bai-Xia Zhang; Xiao-Tong Ye; Ran-Feng Du; Yun Wang; Yan-Jiang Qiao
Journal:  Int J Mol Sci       Date:  2016-10-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.